Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol.

A similarly designed study using everolimus (initiated at 4.5 months post-transplant) in 300 patients also showed a highly significant increase in eGFR at 1 year after transplant (eGFR 71.8 versus 61.9 ml/min/1.73m 2 , P <0.0001) [ 13 ].

also in 132,142 other papers